Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management
Journal of the American Academy of Dermatology · 2026-09
DOI: 10.1016/j.jaad.2026.09.045 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the American Academy of Dermatology, 2026-09. Verfasst von Kevin Hoffman und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Baylor College of Medicine, Houston, Texas. Electronic address: kevin.hoffman@bcm.edu. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Baylor College of Medicine, Houston, Texas. Electronic address: kevin.hoffman@bcm.edu.
- School of Medicine, Baylor College of Medicine, Houston, Texas.
- Department of Dermatology, Baylor College of Medicine, Houston, Texas.
Zitieren
APA
Hoffman, K., Husseinali, M., & Ren, V. (2026). Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.09.045
Vancouver
Hoffman K, Husseinali M, Ren V. Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.09.045
BibTeX
@article{Hoffman2026,
author = {Hoffman, Kevin and Husseinali, Malak and Ren, Vicky},
title = {Off-Label Benefits and Shared Responsibility: Ethical Considerations of GLP-1 Agonists in Psoriasis Management},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
doi = {10.1016/j.jaad.2026.09.045}
}
EUVIMED